SCHEMBL2628618

SCHEMBL2628618

CC(C)[C@@H]1CC[C@@H](C)C[C@H]1C(=O)NCC(O)c1ccc(O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 5/20 0.51
EPHX1 P07099 1/20 0.44
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HTR1A P08908 1/20 0.40
THPO P40225 1/20 0.40
BLM P54132 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NMUR2 Q9GZQ4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP2C9 P11712 1/20 0.40
HIF1A Q16665 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
ADRB2 P07550 1/20 0.39
TRPV1 Q8NER1 4/20 0.39
P2RX4 Q99571 1/20 0.38
MEN1 O00255 1/20 0.37
NTSR1 P30989 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18769833 0.89 TRPM8 (0.52) TRPM8EPHX1KDM4ESMN1; SMN2TAAR1
SCHEMBL2628627 0.89 TRPM8 (0.52) TRPM8EPHX1KDM4ESMN1; SMN2TAAR1
SCHEMBL29112425 0.89 TRPM8 (0.52) TRPM8EPHX1KDM4ESMN1; SMN2TAAR1
SCHEMBL15131599 0.89 TRPM8 (0.52) TRPM8EPHX1KDM4ESMN1; SMN2TAAR1
SCHEMBL2628609 0.89 TRPM8 (0.52) TRPM8EPHX1KDM4ESMN1; SMN2TAAR1
SCHEMBL24540582 0.89 TRPM8 (0.52) TRPM8EPHX1KDM4ESMN1; SMN2TAAR1
SCHEMBL18786371 0.89 TRPM8 (0.52) TRPM8EPHX1KDM4ESMN1; SMN2TAAR1
SCHEMBL890916 0.89 TRPM8 (0.52) TRPM8EPHX1KDM4ESMN1; SMN2TAAR1
SCHEMBL2628626 0.89 TRPM8 (0.52) TRPM8EPHX1KDM4ESMN1; SMN2TAAR1
SCHEMBL24540520 0.87 HIF1A (0.46) TRPM8EPHX1KDM4EHTR1ABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190296-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2013-07-25 US disclosed
US-8389730-B2 Compositions and methods for the treatment of disease associated with TRP-P8 expression DENDREON CORPORATION (US) 2013-03-05 US disclosed
US-8389730-B2 Compositions and methods for the treatment of disease associated with TRP-P8 expression DENDREON CORPORATION (US) 2013-03-05 US disclosed
US-8362264-B2 Tryptophan antagonist; anticancer agents DENDREON CORPORATION (US) 2013-01-29 US disclosed
US-8362264-B2 Tryptophan antagonist; anticancer agents DENDREON CORPORATION (US) 2013-01-29 US disclosed
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2012-04-19 US disclosed
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190296-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION TRPC4, TRPC3, TRPC1 TRPM8 10/4885EPHX1 2902/4885ALDH1A1 4716/4885
US-20120094977-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION TRPC4, TRPC3, TRPC1 TRPM8 8/4885EPHX1 2270/4885ALDH1A1 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.